Simotinib

Simotinib 是一种选择性、特异性、口服生物利用度高的 EGFR 酪氨酸激酶抑制剂，IC50 为 19.9 nM。抗肿瘤活性。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥3775.00

3020.00

- +
10mg

￥6262.00

5010.00

- +
25mg

￥11875.00

9500.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Simotinib is a selective, specific, and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 19.9 nM. Antineoplastic activities[1].

Simotinib inhibits in a dose-dependent manner EGFR and the growth of human A431 tumor cells with high expression of EGFR, with no significant activity on other investigated kinases[1].

Simotinib has been shown to exert its antitumor activity by inhibiting EGFR phosphorylation in nude xenograft model[1].

[1]. Hu XS, et al. Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial. Cancer Manag Res. 2019;11:4449-4459. Published 2019 May 13.